PL3733684T3 - Pochodne kwasu ursodeoksycholowego do leczenia wielotorbielowatości - Google Patents
Pochodne kwasu ursodeoksycholowego do leczenia wielotorbielowatościInfo
- Publication number
- PL3733684T3 PL3733684T3 PL18857390T PL18857390T PL3733684T3 PL 3733684 T3 PL3733684 T3 PL 3733684T3 PL 18857390 T PL18857390 T PL 18857390T PL 18857390 T PL18857390 T PL 18857390T PL 3733684 T3 PL3733684 T3 PL 3733684T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- acid derivatives
- ursodeoxycholic acid
- polycystic diseases
- polycystic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201731488A ES2718240A1 (es) | 2017-12-28 | 2017-12-28 | Desarrollo de nuevos inhibidores selectivos frente a hdac6 derivados del acido ursodecoxicolico |
| EP18857390.1A EP3733684B9 (en) | 2017-12-28 | 2018-12-28 | Ursodeoxycholic acid derivatives for the treatment of polycystic diseases |
| PCT/ES2018/070840 WO2019129913A1 (es) | 2017-12-28 | 2018-12-28 | Derivados de ácido ursodecoxicólico para el tratamiento de enfermedades poliquísticas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3733684T3 true PL3733684T3 (pl) | 2022-07-11 |
Family
ID=65763482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18857390T PL3733684T3 (pl) | 2017-12-28 | 2018-12-28 | Pochodne kwasu ursodeoksycholowego do leczenia wielotorbielowatości |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11833160B2 (pl) |
| EP (1) | EP3733684B9 (pl) |
| DK (1) | DK3733684T3 (pl) |
| ES (2) | ES2718240A1 (pl) |
| HU (1) | HUE058268T2 (pl) |
| PL (1) | PL3733684T3 (pl) |
| WO (1) | WO2019129913A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112390844A (zh) * | 2019-08-12 | 2021-02-23 | 中国科学院成都有机化学有限公司 | 甘氨胆酸酯、其制备方法及甘氨胆酸的制备方法 |
| WO2024124148A1 (en) * | 2022-12-09 | 2024-06-13 | Ohio State Innovation Foundation | Lipid compounds and methods of making and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646316A (en) * | 1994-04-08 | 1997-07-08 | Osteoarthritis Sciences, Inc. | Bile acid inhibitors of metalloproteinase enzymes |
| NZ601655A (en) | 2010-01-22 | 2014-10-31 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2014083229A1 (es) * | 2012-11-28 | 2014-06-05 | Administración General De La Comunidad Autónoma De Euskadi | Uso de inhibidores de metaloproteasas en el tratamiento de enfermedades hepáticas poliquísticas |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| WO2016054208A1 (en) * | 2014-10-03 | 2016-04-07 | Mayo Foundation For Medical Education And Research | Targeting tgr5 to treat disease |
-
2017
- 2017-12-28 ES ES201731488A patent/ES2718240A1/es not_active Withdrawn
-
2018
- 2018-12-28 HU HUE18857390A patent/HUE058268T2/hu unknown
- 2018-12-28 DK DK18857390.1T patent/DK3733684T3/da active
- 2018-12-28 EP EP18857390.1A patent/EP3733684B9/en active Active
- 2018-12-28 PL PL18857390T patent/PL3733684T3/pl unknown
- 2018-12-28 US US16/958,429 patent/US11833160B2/en active Active
- 2018-12-28 WO PCT/ES2018/070840 patent/WO2019129913A1/es not_active Ceased
- 2018-12-28 ES ES18857390T patent/ES2916374T3/es active Active
-
2023
- 2023-07-17 US US18/353,525 patent/US20230390308A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2916374T3 (es) | 2022-06-30 |
| HUE058268T2 (hu) | 2022-07-28 |
| DK3733684T3 (da) | 2022-04-19 |
| US11833160B2 (en) | 2023-12-05 |
| ES2718240A1 (es) | 2019-06-28 |
| US20210137946A1 (en) | 2021-05-13 |
| EP3733684B9 (en) | 2022-05-11 |
| US20230390308A1 (en) | 2023-12-07 |
| EP3733684B1 (en) | 2022-01-26 |
| WO2019129913A1 (es) | 2019-07-04 |
| EP3733684A1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304455B1 (en) | Methods and intermediates for the preparation of bile acid derivatives | |
| IL254288B (en) | C22-, c23- and c24-amino-carbonyl-oxy derivatives of bile acids and their use for treating tgr5-mediated diseases | |
| IL258113A (en) | Methods and intermediates for the preparation bile acid derivatives | |
| EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| PT3169328T (pt) | Derivados de quinolina para o tratamento de doenças inflamatórias | |
| IL246721B (en) | History of 5-benzylisoquinoline for the treatment of cardiovascular diseases | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| ZA201801991B (en) | Process for the preparation of monochloroacetic acid | |
| HUE059048T2 (hu) | Eljárás aminobenzoesav vagy aminobenzoesav-konverzióstermék elõállítására | |
| IL262405A (en) | Methods for preparing obeticholic acid and its derivatives | |
| EP3107534A4 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
| SG11202105465WA (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| HUE058268T2 (hu) | Ursodeoxikolsav-származékok policisztás betegségek kezelésére | |
| EP3283457A4 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
| IL277066A (en) | History of LNA-dicarboxylic acid and process for their preparation | |
| PL3710043T3 (pl) | Fgf10 do leczenia chorób serca | |
| EP3634395A4 (en) | LIXIVAPTAN FORMULATIONS FOR THE TREATMENT OF POLYKYSTOSIS | |
| SG11202004230XA (en) | Caffeic acid derivatives for treating hyperproliferative diseases | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders | |
| IL274455A (en) | Caffeic acid derivatives for treating hyperproliferative diseases | |
| HK40030457A (en) | Caffeic acid derivatives for treating hyperproliferative diseases | |
| HK40015215A (en) | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | |
| HK1259556A1 (zh) | 胆汁酸病症的治疗 |